Lenospread (Piroxicam)

Piroxicam inhibits both COX‑1 and COX‑2 enzymes, which blocks the synthesis of prostaglandins—key chemicals that promote inflammation, pain, and fever. By lowering prostaglandin levels at the site of application, the product reduces local swelling and discomfort.

The appropriate amount and frequency of Lenospread are determined by the prescribing healthcare professional based on the specific condition, severity, and patient factors. Patients should follow the prescriber’s instructions and not exceed the recommended application area.

Safety of topical piroxicam in pregnancy or lactation has not been fully established. Healthcare providers usually weigh potential benefits against risks, and it may be avoided unless clearly needed. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their clinician.

To request Lenospread, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenospread contains piroxicam, which offers a longer duration of action compared with some other topical NSAIDs such as diclofenac. Its non‑selective COX inhibition provides broad anti‑inflammatory coverage, but the choice of product depends on the specific indication, tolerability, and clinician preference.

Lenospread should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not freeze or expose the product to extreme temperatures.

The product is applied topically to the affected skin area, usually in a thin layer, and gently massaged until absorbed. The exact frequency and duration are set by the prescriber, and the treated skin should be clean and dry before application.

Serious risks, though rare, include severe allergic reactions such as angioedema or anaphylaxis, skin ulceration at the application site, and systemic NSAID toxicity that could lead to gastrointestinal bleeding or renal impairment, especially when large skin areas are treated.

Lenospread should be avoided in individuals with known hypersensitivity to piroxicam or any component of the formulation, in patients with active gastrointestinal ulcers, severe renal or hepatic impairment, and on broken or infected skin unless directed by a clinician.